Advice

following a full submission:

boceprevir (Victrelis®) is accepted  for use within NHS Scotland.

Indication under review: Treatment of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon and ribavirin, in adult patients with compensated liver disease who are previously untreated.

In the pivotal, phase III randomised study, addition of boceprevir to current standard therapy in patients with HCV who were previously untreated increased the proportion of patients with HCV who achieved a sustained virologic response.
 

Download detailed advice144KB (PDF)

Download

Medicine details

Medicine name:
boceprevir (Victrelis) Naive Patients
SMC ID:
723/11
Indication:
Treatment of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon and ribavirin, in adult patients with compensated liver disease who are previously untreated.
Pharmaceutical company
MSD
BNF chapter
Infections
Submission type
Full
Status
Accepted
Date advice published
10 October 2011